Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Acquires Morphotek s Cell Line Evolution Business; Morphotek to Use Cash to Finance Trials

NEW YORK, Jan. 6 (GenomeWeb News) - Invitrogen has acquired Morphotek's cell line evolution service business for an undisclosed amount, the company said yesterday.


Under the transaction, Morphotek retained rights to its Human Morphodoma antibody technology platform.


According to Nicholas Nicolaides, Morphotek's president and CEO, funding from this transaction will support current clinical trials as well as future therapeutic candidates.


Invitrogen is now the exclusive provider of the cell line evolution technology, Revolution, to the biotechnology and agricultural industries, Morphotek said.


Financial terms were not disclosed.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.